Sanofi has announced an extension of its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer, made through Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, was initially set to expire on July 16, 2025. It has now been extended until 17:00 Eastern Daylight Saving Time on July 17, 2025.
The tender offer proposes a purchase price of $129.00 per share in cash and includes a non-transferable contractual contingent right per share for potential additional payments up to $6.00 per share upon meeting certain milestones.
As of the previous expiration date, approximately 29,742,419 shares or about 45.85% of Blueprint’s total outstanding shares had been validly tendered and not withdrawn. Additionally, around 23,400,152 shares were tendered by notice of guaranteed delivery.
Continental Stock Transfer & Trust Company is acting as the depositary for the offer. Innisfree M&A Incorporated serves as the information agent for this transaction.
Sanofi emphasizes that holders who have already tendered their shares do not need to take further action due to this extension.
The offer is subject to conditions outlined in the purchase documents filed with the US Securities and Exchange Commission (SEC). The primary condition is that a majority of Blueprint’s common stock must be tendered.
Sanofi describes itself as an R&D-driven biopharma company focused on improving lives through innovative medicines and vaccines. The company trades on EURONEXT under SAN and NASDAQ under SNY.
For more information or inquiries regarding the offer, shareholders can contact Innisfree M&A Incorporated or refer to documents available at no cost from Sanofi’s Investor Relations Team or the SEC website.
